Literature DB >> 15939191

Surgical management of sarcomas.

Edward Y Cheng1.   

Abstract

Nearly all bone and soft tissue sarcomas will require surgical management. Early consultation with a surgeon who is experienced in sarcomas, before a biopsy is performed, will avoid potential errors that may complicate subsequent surgery. Advances in imaging, neoadjuvant therapies, and reconstructive techniques have improved the ability to resect adequately most bone and soft tissue sarcomas. The use of oncologic and functional outcomes assessment tools facilitates the development of improved treatments for sarcoma patients. Results from major centers reveal that most patients who have a nonmetastatic bone or soft tissue sarcoma will survive 5 years after surgery when combined with either chemotherapy or radiation.

Entities:  

Mesh:

Year:  2005        PMID: 15939191     DOI: 10.1016/j.hoc.2005.03.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  6 in total

1.  Current treatment of soft tissue sarcoma.

Authors:  Shawn Steen; Gerald Stephenson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-10

2.  ["Dangerous" cutaneous polyp. Exophytic cutaneous myxofibrosarcoma].

Authors:  B E Paredes; T Mentzel; R Denfeld
Journal:  Hautarzt       Date:  2012-09       Impact factor: 0.751

3.  Tumor rupture predicts early metastasis and poor prognosis in stage III soft tissue sarcomas.

Authors:  Yong Chen; JiHui Hao; Yun Yang; JiLong Yang; XiShan Hao
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

4.  Chemotherapy improves distant control in localized high-grade soft tissue sarcoma of the extremity/trunk.

Authors:  Victoria T Rizk; Arash O Naghavi; Andrew S Brohl; David M Joyce; Odion Binitie; Youngchul Kim; John P Hanna; Jennifer Swank; Ricardo J Gonzalez; Damon R Reed; Mihaela Druta
Journal:  Clin Sarcoma Res       Date:  2020-07-09

5.  A review of controversies in the management of soft tissue sarcomas.

Authors:  S V S Deo; N M L Manjunath; N K Shukla
Journal:  Indian J Surg       Date:  2012-06-20       Impact factor: 0.656

6.  Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.

Authors:  Aaron D Schenone; Jingqin Luo; Luke Montgomery; Daniel Morgensztern; Douglas R Adkins; Brian A Van Tine
Journal:  Cancer Med       Date:  2014-02-27       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.